Overview

This trial is active, not recruiting.

Conditions gastrinoma, glucagonoma, insulinoma, islet cell carcinoma, pancreatic polypeptide tumor, recurrent islet cell carcinoma, somatostatinoma
Treatments temozolomide, capecitabine, laboratory biomarker analysis
Phase phase 2
Sponsor Eastern Cooperative Oncology Group
Collaborator National Cancer Institute (NCI)
Start date May 2013
End date July 2017
Trial size 145 participants
Trial identifier NCT01824875, E2211, NCI-2012-02007, U10CA021115, U10CA180820

Summary

This randomized phase II trial studies how well giving temozolomide with or without capecitabine works in treating patients with advanced pancreatic neuroendocrine tumors. Drugs used in chemotherapy, such as temozolomide and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether temozolomide is more effective with or without capecitabine in treating patients with advanced pancreatic neuroendocrine tumors.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification efficacy study
Intervention model parallel assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
Patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
temozolomide SCH 52365
Given PO
laboratory biomarker analysis
Correlative studies
(Experimental)
Patients receive capecitabine PO BID on days 1-14 and temozolomide PO QD on days 10-14. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
temozolomide SCH 52365
Given PO
capecitabine CAPE
Given PO
laboratory biomarker analysis
Correlative studies

Primary Outcomes

Measure
PFS
time frame: Up to 5 years

Secondary Outcomes

Measure
RR defined by revised RECIST criteria version 1.1
time frame: Up to 5 years
Overall survival
time frame: Up to 5 years
Toxicity rates using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
time frame: Up to 5 years

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Patient must have histologically or pathologically confirmed locally unresectable or metastatic low or intermediate grade pancreatic neuroendocrine tumor, excluding small cell carcinoma - Patient must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria; baseline measurements and evaluations of all sites of disease must be obtained =< 4 weeks prior to randomization and must be acquired by multiphasic CT or contrast magnetic resonance imaging (MRI) - Date of last documented disease progression must be =< 12 months from date of randomization - Patient must not have received prior temozolomide, dacarbazine (DTIC), or capecitabine, or 5-FU (fluorouracil) therapy - Prior everolimus and/or sunitinib therapy is allowed, so long as it was discontinued >= 4 weeks prior to randomization - Concurrent somatostatin analogues are allowed provided that patients - Have been on stable doses for 8 weeks and - Have documented disease progression on that dose - Patients may not be receiving any other investigational agents while on study treatment - Patients may not be receiving Coumadin while on treatment; other anticoagulants are allowed - Leukocytes >= 3,000/mm^3 - Absolute neutrophil count >= 1,500/mm^3 - Hemoglobin >= 9 g/dL - Platelets >= 100,000/mm^3 - Total bilirubin =< institutional upper limit of normal (ULN) or =< 1.5 X institutional ULN (if the patient has liver metastases) - Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 X institutional ULN or (=< 5 X institutional ULN if the patient has liver metastases) - Serum creatinine =< 1.5 X institutional ULN - Patient must have Eastern Cooperative Oncology Group (ECOG) performance status 0-1 - Patient must have life expectancy >= 12 weeks - Patients with either clinically apparent central nervous system metastases or carcinomatous meningitis are ineligible - Patients must NOT have active or uncontrolled infection or serious medical or psychiatric illness - Patients must NOT have history of allergic reactions attributed to compounds of similar chemical or biologic composition to temozolomide or capecitabine - Patient must NOT have absorption issues that would limit the ability to absorb study agents - Patients with a history of the following within =< 12 months of study entry are not eligible: - Arterial thromboembolic events - Unstable angina - Myocardial Infarction - Patients with symptomatic peripheral vascular disease are not eligible - Patients must NOT have previous or concurrent malignancy; exceptions are made for patients who meet any of the following conditions: - Non-melanoma skin cancer, in situ cervical cancer, or breast cancer in situ OR - Prior malignancy completely excised or removed and patient has been continuously disease free for > 5 years OR - Prior malignancy cured by non-surgical modalities and patient has been continuously disease free for > 5 years - Women must not be pregnant or breast-feeding; all females of childbearing potential must have a blood test or urine study within =< 2 weeks prior to randomization to rule out pregnancy; a female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: - Has not undergone a hysterectomy or bilateral oophorectomy; or - Has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months) - Women of childbearing potential and sexually active males must be strongly advised to use an accepted and effective method of contraception or to abstain from sexual intercourse for the duration of their participation in the study; should a woman become pregnant while participating in this study, she should inform her treating physician immediately; if a man impregnates a woman while participating in this study, he should inform his treating physician immediately - Patient must be able to swallow pills - Patient must be able to tolerate CT or magnetic resonance (MR) imaging including contrast agents as required for their treatment and the protocol

Additional Information

Official title A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
Principal investigator Pamela Kunz
Description PRIMARY OBJECTIVES: I. To evaluate progression-free survival (PFS) associated with temozolomide alone or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors. SECONDARY OBJECTIVES: I. To evaluate response rates (RR) associated with temozolomide alone or temozolomide and capecitabine treatment in patients with advanced pancreatic neuroendocrine tumors. II. To evaluate overall survival (OS) associated with temozolomide alone or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors. III. To evaluate the toxicity associated with temozolomide alone or temozolomide and capecitabine treatment in patients with advanced pancreatic neuroendocrine tumors. IV. To evaluate the usefulness of methyl guanine methyltransferase (MGMT) status (by immunohistochemistry [IHC] and promoter methylation) for predicting response in pancreatic neuroendocrine tumor patients treated with either temozolomide or temozolomide and capecitabine. V. To bank radiology images for evaluation of quality, reproducibility, and compliance with computed tomography (CT) methodology. OUTLINE: Patients are randomized to 1 of 2 treatment arms. ARM A: Patients receive temozolomide orally (PO) once daily (QD) on days 1-5. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity. ARM B: Patients receive capecitabine PO twice daily (BID) on days 1-14 and temozolomide PO QD on days 10-14. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months for 2 years, and then every 6 months for 3 years.
Trial information was received from ClinicalTrials.gov and was last updated in March 2016.
Information provided to ClinicalTrials.gov by Eastern Cooperative Oncology Group.
Location data was received from the National Cancer Institute and was last updated in August 2016.